特朗普的关税政策把美国股市拖入了低谷，投资者忧心忡忡。他需要通过虚假的乐观消息给市场注入信心，以期提振股市。果然，释放"正在谈 判"的谎言后，市场暂时回暖了一阵。然而，被中方无情拆穿之后，美国股市恐怕又将遭受打击。种种迹象表明，特朗普政府急于让中美坐到谈判桌 前。然而，这些毕竟都是单方面的试探，而且条件似乎越来越没有诚意。白宫还有官员表示，如果美国大幅削减关税，中国也必须降低壁垒。这些 话都是为了探测中方态度，但结果往往是自讨苦吃。 美国股市被特朗普拖入低谷（资料图） 据环球网报道，针对美国方面多次表示已经和中方就关税问题进行对话，中国驻美国大使馆当天以发言人答记者问的形式作出回应称，有关言论纯 属混淆视听，"据我了解，中美双方并没有就关税问题进行磋商或谈判，更谈不上达成协议。"中国人民大学国际关系学院教授表示，美国频繁释放 中美关税谈判的虚假消息，证明在第一回合的关税博弈中，美国实际上已不占上风。这说明中国坚定维护自身经济利益，并与美国进行博弈的战略 和政策是正确的。 最近，特朗普政府接连向中国释放降温信号。美国财长贝森特说中美关税对峙很难继续。特朗普本人在白宫也表示，不会采取强硬措施，对华关税 太高了，考 ...

Core Viewpoint - Adial Pharmaceuticals has received a new patent for a treatment method targeting a wide range of alcohol-related disorders and opioid-related disorders using its investigational drug AD04, which is tailored for genetically identified patients [1][2][3] Group 1: Patent and Intellectual Property - The newly issued patent number 12,274,692 covers a precision medicine approach for administering AD04 to patients with specific genetic markers related to serotonin [2] - The patent includes claims for treating various alcohol-related disorders, such as alcohol-induced anxiety, bipolar disorder, sexual dysfunction, sleep disorders, gambling disorder, and alcohol withdrawal [2] Group 2: Company Mission and Development - The CEO of Adial Pharmaceuticals emphasized the significance of this patent as a milestone in providing targeted treatments for individuals suffering from alcohol and opioid use disorders [3] - The company is committed to advancing AD04 through clinical development and regulatory pathways to meet the urgent need for effective, personalized addiction treatments [3] Group 3: Product and Clinical Trials - AD04 is a genetically targeted serotonin-3 receptor antagonist aimed at treating Alcohol Use Disorder (AUD) in heavy drinking patients, with promising results from the ONWARD™ pivotal Phase 3 clinical trial [4] - The ONWARD trial demonstrated effectiveness in reducing heavy drinking without significant safety or tolerability concerns [4]

Core Viewpoint - The company, Shengxiang Biotechnology Co., Ltd., has demonstrated significant growth in revenue and profit, driven by its innovative strategies and market expansion in the in vitro diagnostic industry. Financial Performance - In 2024, the company achieved operating revenue of 1,458.06 million yuan, representing a year-on-year increase of 44.78% [35] - The net profit attributable to shareholders, excluding non-recurring gains and losses, was 202.23 million yuan, up 182.25% year-on-year [35] - The net cash flow from operating activities reached 274.45 million yuan, a substantial increase of 530.34% [35] - The basic earnings per share, after excluding non-recurring gains and losses, was 0.34 yuan, reflecting a growth of 183.33% [35] Business Overview - The company focuses on in vitro diagnostics, providing a comprehensive solution that includes diagnostic reagents, instruments, and third-party medical testing services [13][14] - It has developed over 1,000 products and offers more than 2,200 types of testing services, serving over 160 countries and regions globally [24] - The company emphasizes a dual-driven approach of "innovation + service" to enhance its market presence and product accessibility [13] Industry Position - The company has significantly improved its brand recognition and industry standing, being listed in the global top 100 medical device companies for two consecutive years [23] - It has received numerous national and international awards, including the National Science and Technology Progress Award [24] - The company plays a pivotal role in setting industry standards and has contributed to the development of over 20 molecular diagnostic industry standards [23] Market Trends - The in vitro diagnostic market is experiencing rapid growth, particularly in molecular diagnostics, which is becoming increasingly important in public health and personalized medicine [29] - The demand for high-quality, accessible diagnostic products is rising, driven by an increase in health awareness and the need for preventive healthcare [22][33] - The integration of AI technology in diagnostics is expected to enhance efficiency and accuracy in disease detection and management [30] Future Development - The company aims to leverage advancements in molecular diagnostics and AI to expand its product offerings and improve healthcare accessibility [29][30] - There is a growing trend towards consumer healthcare, with an increasing focus on preventive measures and personalized health management solutions [33] - The company is positioned to capitalize on the evolving healthcare landscape, particularly in the context of China's healthcare reforms and the push for improved primary care services [31][33]

Core Viewpoint - The article highlights the importance of cancer prevention and control, particularly focusing on lung cancer, and promotes a series of educational initiatives aimed at improving public awareness and understanding of cancer treatment advancements, specifically in precision medicine and immunotherapy [1]. Group 1: Cancer Prevention and Awareness - The 31st National Cancer Prevention Week is scheduled from April 15 to 21, 2025, aimed at expanding cancer prevention education and encouraging individuals to take responsibility for their health [1]. - The "People's Good Doctor · Camellia Plan" series will feature experts discussing cancer prevention and treatment, fostering a supportive social atmosphere for cancer control [1]. Group 2: Advances in Lung Cancer Treatment - Lung cancer remains the most prevalent and deadly malignancy globally, with significant changes in treatment paradigms due to breakthroughs in precision medicine and immunotherapy [1]. - A live session on April 29 will feature experts sharing insights on how precision medicine and immunotherapy are transforming the survival rates of lung cancer patients [1]. Group 3: Expert Profiles - Liu Anwen, Director of the Lung Cancer Specialty Center at Nanchang University Second Affiliated Hospital, holds multiple leadership roles in oncology associations [2]. - Liu Siyang, a physician at Guangdong Provincial People's Hospital, is involved in clinical research and holds significant positions in clinical trial committees [2]. Group 4: Viewing Instructions - The live broadcast can be accessed through the People's Good Doctor App, specifically in the "Famous Doctor Live" section [3]. - Users can download the app from app stores or follow the instructions provided via the People's Health public WeChat account [4].

Financial Data and Key Metrics Changes - In 2024, the company recorded $1.2 million in revenue, a growth of 59% over 2023 [28] - Revenue from the NUQ VET cancer test was $0.8 million, growing by 75% compared to the prior year [28] - Operating expenses were reduced by 23% year-on-year, with second half operating expenses down 31% [30] - Net cash used in operating activities was $25.9 million in 2024, compared to $18.1 million in 2023 [31] Business Line Data and Key Metrics Changes - Approximately 120,000 NUQ VET cancer tests were sold in 2024, more than double the sales in 2023 [28] - Revenue from the NUQ Discover pillar was approximately $400,000, with a year-on-year growth of 40% [29] - The company recorded its first revenue from the NUQ NETS, marking a significant milestone [29] Market Data and Key Metrics Changes - The NUQ VET cancer test is now available in over 20 countries, expanding access significantly [18] - The point-of-care market is noted to be less than 20% of the total market, indicating growth potential [22] Company Strategy and Development Direction - The company aims to sign multiple licensing deals in 2025, focusing on human applications of its technology [11] - There is a strong interest in potential out-licensing and supply agreements for both NUQ NETS and the oncology portfolio [12] - The strategy includes raising non-dilutive funds, ramping revenues, reducing expenses, and signing commercial deals with large industry players [74] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash neutrality on a full-year basis by 2025 [27] - The company is at a pivotal juncture, ready to revolutionize diagnostics for both animals and humans [12] - Management highlighted the importance of automation in centralized labs to accelerate growth [22] Other Important Information - The company received approximately $1.8 million in non-dilutive funding from Belgian institutions during 2024 [33] - The NUQ platform has shown broad applicability across various established platforms, enhancing its market potential [14] Q&A Session Summary Question: Update on the feline cancer testing program - Management confirmed that the feline cancer testing program is on track for completion later this year, with a milestone payment of $5 million expected upon completion [80] Question: Discussion on the Leon study and its implementation - Management indicated that there are plans for prospective studies following the results of the Leon study, with potential rapid adoption in cancer programs [86][90] Question: Insights on quarterly sales trends and outlook for 2025 - Management noted that sales were lumpy due to large customers ordering in batches, but solid growth was achieved with 120,000 tests sold [100] - Automation in central labs is expected to open up larger opportunities in 2025 [101] Question: Approach to managing financing risks - Management emphasized a tight grip on expenses and cash flows while focusing on securing licensing agreements [112] Question: Activity and interest in data rooms for licensing agreements - Management reported that the data generated exceeded expectations and has been crucial in energizing discussions with major companies [118]